These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2437037)

  • 1. Yeast recombinant hepatitis B vaccine.
    Hilleman MR
    Infection; 1987; 15(1):3-7. PubMed ID: 2437037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of recombinant hepatitis B vaccine.
    Ohmura T; Ohmizu A; Sumi A; Ohtani W; Uemura Y; Arimura H; Nishida M; Kohama Y; Okabe M; Mimura T
    Biochem Biophys Res Commun; 1987 Dec; 149(3):1172-8. PubMed ID: 2962578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological properties of recombinant HBsAg produced in yeast.
    Hauser P; Voet P; Simoen E; Thomas HC; Pêtre J; De Wilde M; Stephenne J
    Postgrad Med J; 1987; 63 Suppl 2():83-91. PubMed ID: 2446304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subunit, recombinant and synthetic hepatitis B vaccines.
    Zuckerman AJ
    Scand J Gastroenterol Suppl; 1985; 117():27-38. PubMed ID: 3912963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules.
    Scheiermann N; Gesemann M; Maurer C; Just M; Berger R
    Vaccine; 1990 Mar; 8 Suppl():S44-6; discussion S60-2. PubMed ID: 2139282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines.
    Shouval D; Ilan Y; Adler R; Deepen R; Panet A; Even-Chen Z; Gorecki M; Gerlich WH
    Vaccine; 1994 Nov; 12(15):1453-9. PubMed ID: 7533967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a purified hepatitis B virus vaccine prepared by using recombinant DNA technology.
    Zahradnik JM; Couch RB; Gerin JL
    J Infect Dis; 1987 May; 155(5):903-8. PubMed ID: 2951449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose range study in healthy volunteers of a hepatitis B vaccine produced in yeast.
    Kuwert E; Scheiermann N; Gesemann M; Paar D; Safary A; Simoen E; Hauser P; Andre F
    Antiviral Res; 1985; Suppl 1():281-8. PubMed ID: 2935080
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children.
    Milne A; Moyes CD; Allwood GK; Pearce NE; Krugman S
    N Z Med J; 1988 Feb; 101(840):67-9. PubMed ID: 2967940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates.
    Gunn TR; Bosley A; Woodfield DG
    N Z Med J; 1989 Jan; 102(860):1-3. PubMed ID: 2521527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study.
    Goh KT; Tan KL; Kong KH; Oon CJ; Chan SH
    Bull World Health Organ; 1992; 70(2):233-9. PubMed ID: 1600584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine.
    Weissman JY; Tsuchiyose MM; Tong MJ; Co R; Chin K; Ettenger RB
    JAMA; 1988 Sep 23-30; 260(12):1734-8. PubMed ID: 2970557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of a recombinant yeast-derived hepatitis B vaccine (Engerix B) in children.
    Moyes C; Milne A
    N Z Med J; 1988 Apr; 101(843):162-4. PubMed ID: 2965799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactogenicity and immunogenicity of a new recombinant yeast-derived hepatitis B vaccine.
    Scheiermann N; Gesemann KM; Paar D; Maurer C
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Nov; 269(3):411-21. PubMed ID: 2975448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of yeast-derived hepatitis B vaccines in young adults.
    Bergamini F; Zanetti A
    Postgrad Med J; 1987; 63 Suppl 2():137-8. PubMed ID: 3317349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine.
    Just M; Berger R; Scheiermann N
    Vaccine; 1988 Oct; 6(5):401-2. PubMed ID: 2973694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production and immunological analysis of recombinant hepatitis B vaccine.
    Emini EA; Ellis RW; Miller WJ; McAleer WJ; Scolnick EM; Gerety RJ
    J Infect; 1986 Jul; 13 Suppl A():3-9. PubMed ID: 2427590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects.
    Ambrosch F; Frisch-Niggemeyer W; Kremsner P; Kunz C; André F; Safary A; Wiedermann G
    Postgrad Med J; 1987; 63 Suppl 2():129-35. PubMed ID: 3317348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers.
    Poovorawan Y; Sanpavat S; Pongpunlert W; Chumdermpadetsuk S; Sentrakul P; Safary A
    JAMA; 1989 Jun; 261(22):3278-81. PubMed ID: 2523981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vaccination against hepatitis virus B infection. Vaccine from inactivated HBsAg positive plasma or recombinant vaccine?].
    Horejsí J
    Cas Lek Cesk; 1987 Jul; 126(31):981-2. PubMed ID: 2959363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.